Reports Q3 revenue $22.6M, consensus $21.78M. “We are encouraged by our third quarter performance, which reflects strong commercial execution and continued momentum in adoption of the Ceribell (CBLL) System,” said co-founder and CEO Jane Chao. “Looking ahead, our focus remains on generating robust clinical evidence to help establish point-of-care EEG as a new standard of care for seizure management in the acute care setting. Our progress this quarter underscores the foundational work we’ve done to unlock what we believe to be a $2 billion addressable market opportunity and reinforces our leadership position built on differentiated technology, extensive clinical and economic data, and continued innovation.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell files $300M mixed securities shelf
- Ceribell, Inc.: Strong Buy Rating Amid Market Potential and Clinical Advancements
- Ceribell’s Delirium Study: A New Frontier in EEG Technology
- Ceribell, Inc.: Innovative EEG System and Market Potential Drive Buy Rating
- Ceribell initiated with a Strong Buy at Raymond James